Join the Novolog group to help and get support from people like you.
Novolog News
Advanced Tech Making Type 1 Diabetes More Manageable
THURSDAY, Aug. 14, 2025 — Advanced technology has boosted the ability of children and adults to manage their type 1 diabetes, a new study says. The number of kids under 18 who’ve achieved optimal con...
Intranasal Administration of PET Radiotracer Delivers Insulin to Multiple Brain Regions
THURSDAY, July 31, 2025 – Intranasal administration of [68Ga]Ga-NOTA-insulin is safe and delivers insulin to multiple brain regions, according to a study published online July 23 in Alzheimer's &...
FDA Approves Kirsty (insulin aspart-xjhz), an Interchangeable Biosimilar to NovoLog
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India: July 15, 2025 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 53...
Barbie's Latest Look? It Includes an Insulin Pump and Glucose Monitor
WEDNESDAY, July 9, 2025 — Barbie’s latest look includes a polka-dot crop top, chunky heels — and an insulin pump. Mattel has released its first-ever Barbie with type 1 diabetes, complete with a gluco...
Stem Cell Treatment May Free Some With Type 1 Diabetes From Insulin
TUESDAY, June 24, 2025 — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 people with severe type 1 diabetes stop using insulin, researchers report. The treatment, c...
Monthly News Roundup - February 2025
FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...
FDA Approves Merilog (insulin-aspart-szjj), a Biosimilar to NovoLog
February 14, 2025 – Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to NovoLog (insulin aspart) for the improvement of glycemic control in adults...
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 – The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with...
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 – The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with...
Automated Insulin Delivery System Improves Glycemic Control in Youth
THURSDAY, Dec. 12, 2024 – Initiation of an automated insulin delivery (AID) system improves glycemic control in children and adolescents with type 1 diabetes (T1D), according to a study published in...
FDA Medwatch Alert: Novo Nordisk Issues Voluntary Nationwide Recall of Levemir, Tresiba, Fiasp, Novolog and Xultophy Product Samples Due to Improper Storage Temperature Conditions
May 10, 2021 – Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are b...
FDA Medwatch Alert: Caution When Using Pen Needles to Inject Medicines: FDA Safety Communication
Audience: Patients and caregivers who use or are considering using pen injectors with pen needles to inject prescription medicines. Health care providers who treat patients, or who train...
Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin
PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting...
FDA Medwatch Alert: NovoLog insulin aspart [rDNA origin] injection)
[Posted 09/14/2005] Novo Nordisk Incorporated and FDA notified pharmacists of an initiative implemented to help prevent dispensing errors. To facilitate the dispensing of the correct product, color...
Further information
Related condition support groups
Diabetes, Type 2, Diabetes, Type 1